Pharmacokinetics and Safety of an Antirhinoviral Agent, Ruprintrivir, in Healthy Volunteers

A single-dose study and a multiple-dose study of the safety and pharmacokinetics of ruprintrivir, a new selective irreversible inhibitor of human rhinovirus 3C protease, were conducted with healthy adult volunteers. Both studies were double-blind, randomized, placebo-controlled, parallel-group inves...

Täydet tiedot

Bibliografiset tiedot

Julkaisussa:	Antimicrob Agents Chemother
Päätekijät:	Hsyu, Poe-Hirr, Pithavala, Yazdi K., Gersten, Merril, Penning, Carol A., Kerr, Bradley M.
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	American Society for Microbiology (ASM) 2002
Aiheet:	Pharmacology
Linkit:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC127051/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11796347/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.46.2.392-397.2002
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!